NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021.

Journal Article (Journal Article)

Hepatosplenic T-cell lymphoma (HSTCL) is a rare subtype of T-cell lymphoma associated with an aggressive clinical course and a worse prognosis. HSTCL develops in the setting of chronic immune suppression or immune dysregulation in up to 20% of cases and is most often characterized by spleen, liver, and bone marrow involvement. Diagnosis and management of HSTCL pose significant challenges given the rarity of the disease along with the absence of lymphadenopathy and poor outcome with conventional chemotherapy regimens. These Guidelines Insights focus on the diagnosis and treatment of HSTCL as outlined in the NCCN Guidelines for T-Cell Lymphomas.

Full Text

Duke Authors

Cited Authors

  • Horwitz, SM; Ansell, S; Ai, WZ; Barnes, J; Barta, SK; Clemens, MW; Dogan, A; Goodman, AM; Goyal, G; Guitart, J; Halwani, A; Haverkos, BM; Hoppe, RT; Jacobsen, E; Jagadeesh, D; Jones, A; Kim, YH; Mehta-Shah, N; Olsen, EA; Pro, B; Rajguru, SA; Rozati, S; Said, J; Shaver, A; Shustov, A; Sokol, L; Torka, P; Torres-Cabala, C; Wilcox, R; William, BM; Zain, J; Dwyer, MA; Sundar, H

Published Date

  • November 2, 2020

Published In

Volume / Issue

  • 18 / 11

Start / End Page

  • 1460 - 1467

PubMed ID

  • 33152703

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2020.0053

Language

  • eng

Conference Location

  • United States